Retension Pharmaceuticals, Inc. (RTSN) shareholders
Close on Nov 18, 2026Market cap $11.22MP/E –Yield –
Ownership
Who owns Retension Pharmaceuticals's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Pvg Asset Management Corp | 1,002,050 | 8.30% | 13G (passive) | Oct 9, 2026 |
| The B Group, Inc. Joint filing with B Group Capital LLC (10.00%), Branden B. Muhl (10.00%) | 833,333 | 10.00% | 13G (passive) | Oct 13, 2026 |
| Laurence W. Lytton | 617,207 | 7.40% | 13G (passive) | Oct 13, 2026 |
| Eric Keller | 598,598 | 7.07% | 13D (active) | Oct 13, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Eric L. Keller | CHIEF EXECUTIVE OFFICER, Director | 464,407 | Oct 22, 2026 |
| Robert Wong | VP, Chief Accounting Officer | – | Nov 4, 2026 |
| Sabine Bisson | CHIEF OPERATING OFFICER | 4,115 | Oct 13, 2026 |
| Paul Sweetnam | CHIEF SCIENTIFIC OFFICER | 409,243 | Oct 13, 2026 |
| Alison D. Schecter | Chief Medical Officer | – | Oct 8, 2026 |
| Alexander Duke Schwartz | Chief Financial Officer | – | Oct 8, 2026 |
| Michael J. Berendt | Director | 6,666 | Oct 13, 2026 |
| Franklin M. Berger | Director | 22,517 | Oct 13, 2026 |
| Donald Olds | Director | 5,637 | Oct 13, 2026 |
| Pavan Cheruvu | Director | – | Oct 13, 2026 |
| B Group, Inc. | 10% owner | 833,333 | Oct 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Eric L. Keller CHIEF EXECUTIVE OFFICER, Director | Oct 13, 2026 | Conversion | +31,368 | – | – | 464,407 |
| Eric L. Keller CHIEF EXECUTIVE OFFICER, Director | Oct 13, 2026 | Conversion | +9,662 | – | – | 433,039 |
| Eric L. Keller CHIEF EXECUTIVE OFFICER, Director | Oct 13, 2026 | Buy | +20,800 | $12.00 | $249.60K | 423,377 |
| Paul Sweetnam CHIEF SCIENTIFIC OFFICER | Oct 13, 2026 | Conversion | +2,640 | – | – | 2,640 |
| Paul Sweetnam CHIEF SCIENTIFIC OFFICER | Oct 13, 2026 | Conversion | +4,026 | – | – | 406,603 |
| Donald Olds Director | Oct 13, 2026 | Conversion | +5,637 | – | – | 5,637 |
| Sabine Bisson CHIEF OPERATING OFFICER | Oct 13, 2026 | Conversion | +2,504 | – | – | 4,115 |
| Sabine Bisson CHIEF OPERATING OFFICER | Oct 13, 2026 | Conversion | +1,611 | – | – | 1,611 |
| Franklin M. Berger Director | Oct 13, 2026 | Buy | +10,000 | $12.00 | $120.00K | 10,000 |
| Franklin M. Berger Director | Oct 13, 2026 | Conversion | +12,517 | – | – | 12,517 |
| Michael J. Berendt Director | Oct 13, 2026 | Conversion | +2,640 | – | – | 6,666 |
| Michael J. Berendt Director | Oct 13, 2026 | Conversion | +4,026 | – | – | 4,026 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Retension Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 32,377 shares on Oct 13, 2026 over the last 90 days.
See a number that looks wrong?